The sales of diabetes medicine in Spain have shown a general upward trend from 2013 to 2023. In 2023, the sales stood at 2.42 billion USD. Notably, the recent years of 2022 and 2023 saw variations of -3.77% and 5.5%, respectively. The compound annual growth rate (CAGR) over the last five years up to 2023 was 5.11%, indicating steady growth despite yearly fluctuations. Looking ahead, from 2024 to 2028, the forecasted CAGR is expected to be around 2.67%, showing a more moderated increase with a total growth rate of 14.08% over this period.

Future trends to watch for:

Continued innovation in diabetes treatments and technology could drive further growth.
The aging population and lifestyle changes in Spain may increase the prevalence of diabetes, thereby boosting medicine demand.
Government health policies and pricing regulations could impact sales trends significantly.